Determining the epigenetic synergy of a repurposed drug and identification of prognosis-related lncRNAs in liver cancer and hematologic malignancies

Abstract

<strong>Background:</strong> Epigenetics is crucial in cancer research, revealing its impact on diverse cancer types' development and progression. Epigenetic-targeting drugs show promise in improving patient outcomes, but addressing their potential side effects is also important. Liver cancer and hematological malignancies pose a significant global health burden with high incidence and mortality rates. Further research is needed to explore new treatments and targets for them. Drug repurposing, such as metformin, offers a promising approach by leveraging non-oncology drugs with anticancer effects and low side effects. This strategy holds potential for discovering new therapeutic options. <br /> <strong>Aims:</strong> This dissertation explores the role of epigenetics in cancer by investigating two primary research objectives: 1) the potential benefits of repurposing market-available drugs for epigenetic therapy as novel anticancer treatments; 2) the identification of long non-coding RNAs (lncRNAs) in cancers for prognosis prediction and the identification of potential therapeutic targets. <br /> <strong>Method:</strong> In the first publication, we investigated the anticancer properties of meticrane, a diuretic medication, in liver cancer and hematological malignancies. Additionally, we assessed the synergistic effects of meticrane when combined with epigenetic drugs for cancer treatment. In our subsequent publications, we employed bioinformatic analysis to identify potential lncRNAs associated with the survival of cancer patients. <br /> <strong>Results:</strong> Meticrane demonstrated anticancer effects in liver cancer and leukemia. Furthermore, it exhibited additive or synergistic effects when used in combination with epigenetic drugs against both liver cancer and leukemia. In addition, our research identified several lncRNAs that are associated with the prognosis of cancer patients. Conclusion: The non-oncology drug meticrane exhibited an anticancer effect and demonstrated additive or synergistic effects when combined with epigenetic drugs in the treatment of cancers (liver cancer and leukemia).